Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
RESEARCH TOOLSreports
Holding ARQT?
Track your performance easily
ARQT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.76 - $13.17
Previous Close$10.37
Volume1.23M
Average Volume (3M)2.41M
Market Cap
$1.22B
Enterprise Value$1.06B
Total Cash (Recent Filing)$362.44M
Total Debt (Recent Filing)$207.56M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Nov 06, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding116,891,023
10 Day Avg. Volume1,474,937
30 Day Avg. Volume2,411,377
Standard Deviation0.27
R-Squared0.06
Alpha0.00873
Financial Highlights & Ratios
Price to Book (P/B)6.52
Price to Sales (P/S)8.99
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.01
Enterprise Value/Gross Profit19.36
Enterprise Value/Ebitda-6.28
Forecast
1Y Price Target
$16.80Price Target Upside61.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Arcutis Biotherapeutics News
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe launch of Zoryve cream into atopic dermatitis (AD) is underway, with the previously announced partnership with Kowa providing commercial capabilities addressing the primary care market.
Product ApprovalZoryve cream 0.15% received FDA approval for the treatment of mild-to-moderate atopic dermatitis in adults and children aged ≥6 yrs.
Sales PerformanceARQT reported total 2Q24 sales of $30.9MM (+43% Q/Q) above the Street's $29.1MM, driven by strength from both the cream ($17.3MM, +15% Q/Q) and foam ($13.6MM, +109% Q/Q) products.
Bears Say
Market ReactionThe slight delay from the PDUFA frayed some nerves and put ARQT shares under pressure.
Prescription TrendsNRxs of Zoryve Cream were down 19.9% from the prior week's 2,306 NRxs.
Sales PerformanceZoryve cream sales in psoriasis of $17.3 million were below both analyst and consensus estimates.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $1.76 and its highest was $13.17 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Currently, no data Available
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 49 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Aug 14, 2024. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.516 by $0.096.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is -$0.41.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 116,891,020 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.516. Following the earnings report the stock price went down -11.273%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Among the largest hedge funds holding Arcutis Biotherapeutics’s share is Gilder Gagnon Howe & Co LLC.. It holds Arcutis Biotherapeutics’s shares valued at 34M.
---
Arcutis Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.80 (61.54% Upside)
$16.80 (61.54% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $107.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.27%
12-Months-Change
Fundamentals
Return on Equity
-148.92%
Trailing 12-Months
Asset Growth
38.69%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
---
ARQT Company Deck
---
ARQT Earnings Call
Q2 2024
0:00 / 0:00
---
ARQT Stock 12 Month Forecast
Average Price Target
$16.80
▲(61.54% Upside)
Technical Analysis
Best Analysts Covering ARQT
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
+27.16%
reiterated a buy rating last month
Copying Serge Belanger's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +27.16% per trade.
---